Renal medullary carcinoma (RMC) is a rare and aggressive form of kidney cancer that can be difficult to distinguish from other tumor types. According to a recent report, the well-established radiotracer 18F-FDG demonstrates consistently strong uptake in RMC, making it a reliable marker on PET/CT imaging. This contrasts with many other kidney cancers, where FDG uptake is often inconsistent or low, which can complicate diagnosis.
The study found that 18F-FDG PET/CT remained highly effective even after patients had received systemic treatment, suggesting the tracer's utility extends beyond initial staging. In addition, the imaging method uncovered extra sites of disease that had not been previously detected, which could influence treatment planning and monitoring.
Because the report is based on a single source, there is no independent comparison to note. However, the findings highlight a practical use of an already approved radiotracer for a challenging cancer subtype, potentially offering clinicians a straightforward tool to improve detection and management of RMC.